EDIT
Editas Medicine, Inc.Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-17 | Scadden David |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027. |
Stock Option (right to buy)
|
51,700 |
| 2026-06-17 | Hopfield Jessica |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027. |
Stock Option (right to buy)
|
51,700 |
| 2026-06-17 | Hirsch Andrew |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027. |
Stock Option (right to buy)
|
51,700 |
| 2026-06-17 | Levy Elliott M. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027. |
Stock Option (right to buy)
|
51,700 |
| 2026-06-17 | Connaughton Bernadette |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027. |
Stock Option (right to buy)
|
51,700 |
| 2026-06-03 | O'Neill Gilmore Neil |
Director, CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7250. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
15,380 |
| 2026-06-03 | Burkly Linda |
EVP, CHIEF SCIENTIFIC OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7050. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
731 |
| 2026-06-03 | Parison Amy |
SVP, Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7049. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
464 |
| 2026-03-12 | O'Neill Gilmore Neil |
Director, CEO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on March 12, 2026 and is scheduled to vest over four years in equal monthly installments beginning on April 12, 2026 through March 12, 2030. |
Stock Option (right to buy)
|
1,015,200 |
| 2026-03-12 | Parison Amy |
SVP, Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on March 12, 2026 and is scheduled to vest over four years in equal monthly installments beginning on April 12, 2026 through March 12, 2030. |
Stock Option (right to buy)
|
292,856 |
| 2026-03-12 | Burkly Linda |
EVP, CHIEF SCIENTIFIC OFFICER |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on March 12, 2026 and is scheduled to vest over four years in equal monthly installments beginning on April 12, 2026 through March 12, 2030. |
Stock Option (right to buy)
|
292,856 |
| 2026-03-03 | O'Neill Gilmore Neil |
Director, CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $2.0050 to $2.0204 The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
5,394 |
| 2026-03-03 | Burkly Linda |
EVP, CHIEF SCIENTIFIC OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $2.0041 to $2.0204. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected |
Common Stock
|
749 |
| 2026-03-03 | Parison Amy |
SVP, Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $2.0050 to $2.0204. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
474 |
| 2025-12-03 | O'Neill Gilmore Neil |
Director, CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. |
Common Stock
|
5,603 |
| 2025-12-03 | Burkly Linda |
EVP, CHIEF SCIENTIFIC OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. |
Common Stock
|
713 |
| 2025-12-03 | Parison Amy |
SVP, Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. |
Common Stock
|
461 |
| 2025-09-03 | Burkly Linda |
EVP, CHIEF SCIENTIFIC OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. The amount of securities beneficially owned following the reported transaction includes 5,802 shares acquired under the Issuer's Employee Stock Purchase Plan. |
Common Stock
|
710 |
| 2025-09-03 | O'Neill Gilmore Neil |
Director, CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. |
Common Stock
|
5,592 |
| 2025-09-03 | Parison Amy |
SVP, Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. |
Common Stock
|
458 |
| 2025-08-07 | Parison Amy |
SVP, Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 6, 2025. The sale does not represent a discretionary trade by the Reporting Person. |
Common Stock
|
679 |
| 2025-07-31 | Burkly Linda |
EVP, CHIEF SCIENTIFIC OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on July 24, 2025. The sale does not represent a discretionary trade by the Reporting Person. |
Common Stock
|
5,121 |
| 2025-06-06 | Levy Elliott M. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on June 6, 2025 and is scheduled to vest in full on June 6, 2026. |
Stock Option (right to buy)
|
37,500 |
| 2025-06-06 | Scadden David |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on June 6, 2025 and is scheduled to vest in full on June 6, 2026. |
Stock Option (right to buy)
|
37,500 |
| 2025-06-06 | Hopfield Jessica |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on June 6, 2025 and is scheduled to vest in full on June 6, 2026. |
Stock Option (right to buy)
|
37,500 |
| 2025-06-06 | Hirsch Andrew |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on June 6, 2025 and is scheduled to vest in full on June 6, 2026. |
Stock Option (right to buy)
|
37,500 |
| 2025-06-06 | Connaughton Bernadette |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on June 6, 2025 and is scheduled to vest in full on June 6, 2026. |
Stock Option (right to buy)
|
37,500 |
| 2025-06-03 | Burkly Linda |
EVP, CHIEF SCIENTIFIC OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $1.7239 to $1.7522. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
726 |
| 2025-06-03 | Parison Amy |
SVP, Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2025. The sale does not represent a discretionary trade by the Reporting Person This transaction was executed in multiple trades at prices ranging from $1.7239 to $1.7522. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
446 |
| 2025-06-03 | O'Neill Gilmore Neil |
Director, CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $1.7239 to $1.7566 . The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
15,192 |
| 2025-04-08 | Parison Amy |
SVP, Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on April 8, 2025 and is scheduled to vest over four years, with 25% of the shares to vest on April 8, 2026 and the remaining 75% of the shares scheduled to vest in equal monthly monthly installments thereafter through April 8, 2029. |
Stock Option (right to buy)
|
34,672 |
| 2025-03-08 | Lucera Erick |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on March 8, 2025 and is scheduled to vest over four years in equal monthly installments beginning on April 8, 2025 through March 8, 2029. |
Stock Option (right to buy)
|
275,100 |
| 2025-03-08 | O'Neill Gilmore Neil |
Director, CEO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on March 8, 2025 and is scheduled to vest in full on September 8, 2026. |
Stock Option (right to buy)
|
175,000 |
| 2025-03-08 | Burkly Linda |
EVP, CHIEF SCIENTIFIC OFFICER |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on March 8, 2025 and is scheduled to vest in full on September 8, 2026. |
Stock Option (right to buy)
|
70,000 |
| 2025-03-08 | Burkly Linda |
EVP, CHIEF SCIENTIFIC OFFICER |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on March 8, 2025 and is scheduled to vest over four years in equal monthly installments beginning on April 8, 2025 through March 8, 2029. |
Stock Option (right to buy)
|
275,100 |
| 2025-03-08 | O'Neill Gilmore Neil |
Director, CEO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on March 8, 2025 and is scheduled to vest over four years in equal monthly installments beginning on April 8, 2025 through March 8, 2029. |
Stock Option (right to buy)
|
828,000 |
| 2025-03-08 | Lucera Erick |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on March 8, 2025 and is scheduled to vest in full on September 8, 2026. |
Stock Option (right to buy)
|
70,000 |
| 2025-03-04 | Lucera Erick |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 12, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 3, 2025. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $1.7107 to $1.7150 . The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
4,109 |
| 2025-03-04 | Burkly Linda |
EVP, CHIEF SCIENTIFIC OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2025. The sale does not represent a discretionary trade by the Reporting Person. |
Common Stock
|
2,891 |
| 2025-03-04 | O'Neill Gilmore Neil |
Director, CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 3, 2025. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $1.7107 to $1.7125 . The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
16,632 |
| 2024-12-03 | Mei Baisong |
EVP, CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 14, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $2.0507 to $2.0783. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
541 |
| 2024-12-03 | O'Neill Gilmore Neil |
Director, CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $2.0550 to $2.0783. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
1,618 |
| 2024-09-04 | O'Neill Gilmore Neil |
Director, CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $3.4246 to $3.4503. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
1,555 |
| 2024-09-04 | Mei Baisong |
EVP, CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 14, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $3.4246 to $3.4501. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
518 |
| 2024-07-25 | Burkly Linda |
EVP, CHIEF SCIENTIFIC OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on July 24, 2024. The sale does not represent a discretionary trade by the Reporting Person. |
Common Stock
|
11,886 |
| 2024-07-19 | Mei Baisong |
EVP, CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 14, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on July 18, 2024. The sale does not represent a discretionary trade by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $5.1650 to $5.2058. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Common Stock
|
6,619 |
| 2024-06-04 | O'Neill Gilmore Neil |
Director, CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. |
Common Stock
|
12,191 |
| 2024-06-04 | Mei Baisong |
EVP, CHIEF MEDICAL OFFICER |
Sell↓
Filing footnotes — Common Stock (Direct)
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 14, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. |
Common Stock
|
511 |
| 2024-05-30 | Hopfield Jessica |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025. |
Stock Option (right to buy)
|
25,000 |
| 2024-05-30 | Reeve Emma |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025 |
Stock Option (right to buy)
|
25,000 |